Novo's Victoza Leads to Greater Weight Loss Than Byetta

Novo Nordisk A/S (NOVOB) said patients taking its Victoza diabetes drug had greater weight loss than those using Amylin Pharmaceuticals Inc. (AMLN)’s Byetta or a class of drug known as DPP-4 inhibitors.

Novo is presenting the data at the American Diabetes Association’s annual meeting in Philadelphia today. The company, which is studying Victoza as a possible obesity treatment, commented in an e-mailed statement.

Patients taking Victoza lost 3.9 kilograms (8.6 pounds) on average, compared with 0.8 kilogram for those on DPP-4 drugs and 2.9 kilograms for those taking Byetta, Novo Nordisk said.

To contact the reporter on this story: Phil Serafino in Paris at pserafino@bloomberg.net

To contact the editor responsible for this story: Phil Serafino at pserafino@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.